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Diethylnitrosamine (DEN) is a representa-
tive chemical of a family of carcinogenic N-
nitroso compounds. DEN has been found in
workplaces, processed meats, tobacco smoke,
and whiskey (1–3). It may also be derived
from metabolism of some therapeutic drugs
(4). The International Agency for Research
on Cancer concluded that DEN was car-
cinogenic in all animal species and that there
was sufficient evidence of a carcinogenic
effect to classify DEN as a probable human
carcinogen, despite the lack of epidemiologic
data [for review, see Verna et al. (3)].
Administration of DEN to animals has been
shown to cause cancer in liver and, at lower
incidences, in other organs as well (1–3). 
In liver cancer research with experimen-
tal animals, DEN is used either as a com-
plete carcinogen or as an initiator in
multistage models (5). When used as a
tumor initiator, DEN is usually given at a
single dose of 200 mg/kg to induce pro-
nounced liver necrosis and presumably cer-
tain gene mutations in some hepatocytes
(5–7). During the subsequent liver regenera-
tion triggered by the gross necrosis, these
gene mutations are inherited by the daughter
hepatocytes before being corrected by the
DNA repair systems; initiated cells are thus
generated. Unlike most other hepatocytes,
these genetically altered, initiated cells have
acquired resistance to toxic effects of various
chemicals or xenobiotics during the initia-
tion; this feature, usually designated “resis-
tant phenotype,” is the basis for why many
tumor-promoting agents can selectively pro-
mote proliferation of initiated cells (6,8,9).
In many animal models of multistage hepa-
tocarcinogenesis, various tumor promoters
are usually administered to the animals 2
weeks after the initiation with the necrogenic
dose of DEN, at a time when the liver is
recovered morphologically to the normal
from the necrosis (5–7). This principle is
well exempliﬁed by the resistant-hepatocyte
model (6), an experimental regimen that has
been widely used for liver cancer studies in
the rat. In this model, rats are intraperi-
toneally injected with DEN at a dose of 200
mg/kg and 2 weeks later are treated for 2
weeks with 2-acetylaminofluorene (2-AAF)
as the promoting agent. A partial hepatec-
tomy is performed in the middle of the
2-AAF treatment to promote the prolifera-
tion of the initiated, 2-AAF-resistant hepato-
cytes to form tumors. 
Besides inducing liver necrosis, a single
necrogenic dose of DEN to rats can also
cause a decrease in the level of hepatic growth
hormone (GH) receptor (10), the expression
of which is partly regulated by GH (11).
Furthermore, degenerating and dying soma-
totropes have been reported in the pituitary
from rats bearing malignant hepatomas
induced by long-term, low-dose treatment of
DEN (12). These data raise the question of
whether the pituitary, otherwise shown to be
refractory to toxic effects of chemicals (13),
might be a target for DEN toxicity.
Spontaneous liver cancer in both humans
and animals occurs predominantly in males
(14–19). Also, liver cancer induced in vari-
ous experimental animal models usually
shows a male predominance (14,17), as
exemplified by the resistant hepatocyte
model (20,21). Several studies have shown
that liver cancer formation induced by
chemicals in animals can be affected greatly
by various hormonal manipulations, such as
hypophysectomy and castration, demon-
strating the importance of hormones in the
carcinogenic process (14,17,19–21). In addi-
tion, administration of some carcinogens has
been shown to inﬂuence the hormonal envi-
ronment and the sensitivity of tissues to hor-
mones. For instance, treatment of male rats
with 2-AAF decreased the serum level of
testosterone (22), whereas treatment with
some carcinogenic hydrocarbons, such as
3-methylcholanthrene, 2-anthramine, and
benzo[a]pyrene, markedly potentiated the
androgenic effects of synthetic androgens
given simultaneously (23).
Expression and activities of many liver
metabolic enzymes in the rat also exhibit sex
differences. Such sexual differentiation is
controlled mainly by the sexual dimorphism
in the GH secretory pattern via the hypothal-
amo-pituitary-liver axis (24–27). GH secre-
tion in male rats is characterized by low basal
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The acute toxicity of diethylnitrosamine (DEN) to the liver has been well documented in the lit-
erature, but whether DEN also affects the endocrine parameters has been addressed in only a few
studies. We thus investigated the effects of DEN on pituitary, serum hormone levels, and certain
sex-differentiated liver enzymes in this study. Adult male Wister rats were intraperitoneally
injected with DEN at a single dose of 200 mg/kg and were sacriﬁced at 1, 3, 7, and 35 days after
injection; DEN-treated females were included as controls at days 7 and 35. Electron microscopic
observation showed that during the first week after injection, all types of granular cells of the
anterior pituitary in male animals exhibited cellular damage, including disrupted organelles and
cellular structure, as well as pyknotic or lytic nuclei. Many undamaged secretory cells exhibited
dilated endoplasmic reticula, hypertrophic Golgi complexes, and peripheral location of secretory
granules, which usually are morphologic features of increased cellular activities. In male rats, the
serum level of total testosterone decreased and the corticosterone increased 1 day after DEN treat-
ment. The serum level of growth hormone (GH) decreased and the prolactin level increased on
day 3. The hepatic expression of the male-speciﬁc cytochrome P450 2C11 (CYP2C11) decreased
to 1–5% of the normal levels during the ﬁrst week and was still 50% lower than the normal level
on day 35, whereas the female-speciﬁc CYP2C12 expression increased only slightly. Activities of
the male predominant 16α , 16β, and 6β  hydroxylation of androstenedione by microsome
decreased in an in vitro assay, whereas the non–sex-differentiated 7α hydroxylation and the
female-predominant 5α reduction of androstenedione were unaffected. In female rats, decreased
serum GH level was observed on day 7. The CYP2C12 expression in females was decreased to
about 1% and 80% of the normal levels on day 7 and day 35, respectively, but the CYP2C11
expression was unchanged. These data suggest that in male rats, DEN treatment may cause pitu-
itary damage, disturb serum hormone levels, and induce long-lasting reduction of sexual dimor-
phism in certain liver functions. Key words: cytochrome P450, diethylnitrosamine, pituitary,
sexual dimorphism. Environ Health Perspect 109:943–947 (2001). [Online 28 August 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p943-947liao/abstract.htmllevel with regular surges, whereas in females
the secretion is manifested by higher basal
levels with smaller and more irregular pulses
(24–27). The sex differences in the GH
secretory pattern and in liver metabolism are
established mainly by androgen imprinting at
the hypothalamic level soon after birth in
male animals (24–27). Maintenance of these
sex differences during adulthood also requires
a normal level of circulating androgen in
males. Without the male level of circulating
androgen, as in the normal females, GH
secretion and liver metabolism will follow the
female pattern (24–27). 
To understand the effects of DEN on the
endocrine system and the mechanisms for the
sex differences in the animal hepatocarcino-
genesis initiated by DEN, we designed the
present experiment to study the effects of
DEN on the pituitary ultrastructure, serum
levels of several hormones, as well as expres-
sion and activities of several sex-differentiated
liver enzymes. The results showed that DEN,
when given to male rats at a dose of 200
mg/kg, can cause pituitary damage, disturb
the serum hormone levels, and reduce the
sexual dimorphism of certain liver functions.
Materials and Methods
Male and female Wistar rats (ALAB,
Sollentuna, Sweden) were kept under stan-
dardized conditions (light from 0600 hr to
1800 hr, 21 ± 1°C) with food and water
supplied ad libitum. At 7 weeks of age, rats
received an intraperitoneal injection of DEN
(200 mg/kg; Fluka, Buchs, Switzerland) or
saline. Male rats (four to five per group)
were sacrificed by decapitation between
0930 and 1030 hr 1, 3, 7, and 35 days after
dosing. Age-matched, untreated males were
included as controls at days 1, 7, and 35;
control animals for day 1 were also used for
day 3. DEN-treated and untreated females
(ﬁve per group) were sacriﬁced on day 7 and
day 35.
At sacriﬁce the pituitaries were carefully
isolated. Anterior pituitary tissue was cut
into about 1-mm3 blocks, immediately
immersed in precooled fixative (1.5% glu-
taraldehyde, 0.3% paraformaldehyde, 3 mM
CaCl2, 0.1 M sodium cacodylate buffer),
and embedded with Epon LX112 by routine
procedures. Semithin sections were stained
with toluidine blue or hematoxylin-eosin for
light microscopy. Ultrathin sections were
made from areas selected under light micro-
scope and analyzed under a Philips 400-T
model electron microscope (Philips Nederland
B.V. Business Communications, Boschdijk,
The Netherlands).
We allowed blood samples collected
from decapitation to clot at 4°C. After cen-
trifugation, the serum was separated and
stored at –20°C. We measured serum levels
of GH, corticosterone, and total testosterone
with radioimmunoassays as described previ-
ously (28–30), using commercial antibody
kits (Diagnostic Products Corporation, Los
Angeles, CA, USA) for GH, corticosterone,
and testosterone. We measured the serum
level of prolactin with the same method by
using an antibody kit from the Pituitary
Program, National Institute of Arthritis,
Diabetes and Digestive and Kidney Diseases,
National Institutes of Health (29,30).
Liver tissue collected at sacrifice was
frozen in liquid nitrogen and stored at –70°C.
Total nucleic acids (TNA) were prepared
according to Durnam and Palmiter (31). We
measured mRNA expression by hybridization
of TNA samples to [35S]UTP-labeled cRNA
probes in solution and at conditions described
previously (32–34). We synthesized cRNA
probes from a 190-bp cDNA fragment
cloned from the 3´-untranslated region of the
cytochrome P450 2C11 (CYP2C11) gene or
from a 50-bp oligonucleotide synthesized
from a determined sequence of the CYP2C12
gene (32–34). We synthesized β -actin cRNA
from a 2-kb fragment of chicken brain
cDNA. The mRNA expression of both CYPs
was presented as attomole (amol; 10–18 mole)
per microgram TNA; the methods for cali-
bration and standardization of the expression
of CYP2C11 and CYP2C12 mRNA are
described in detail by Mode et al. (32).
We prepared microsomal fractions from
the liver of male rats 7 days after DEN treat-
ment as previously described (35), froze
them in liquid nitrogen, and stored them at
–70°C. We measured in vitro microsomal
metabolism of 4-[4-C14]androstene-3,17-
dione (Amersham, Uppsala, Sweden) as pre-
viously described (35). We performed
Western blot analyses using monoclonal
antibodies against CYP2C11 and CYP2C12
(33) and goat anti-mouse IgG conjugated
with horseradish peroxidase (Bio-Rad,
Richmond, CA, USA). Twenty and 40 µg
microsomal proteins per lane for CYP2C11
and CYP2C12, respectively, were fractionated
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Figure 1. Electron micrograph showing normal
somatotropes (S) and follicle-stimulating hormone
gonadotropes (F) as well as normal capillary in a
male control pituitary. Magniﬁcation × 5,900.
Figure 2. Electron micrograph showing pituitary
hemorrhage 1 day after DEN treatment in a male
rat. Erythrocytes (E) directly touch cytoplasm and
organelles of a follicle-stimulating hormone
gonadotrope (F), the cell membrane of which is
disrupted. Magniﬁcation × 7,900.
Figure 3. Electron micrograph showing various
degenerative changes 1 day after DEN treatment in
a corticotrope (C), a somatotrope (S), a follicle-stim-
ulating hormone gonadotrope (F), a lactotrope (L), a
thyrotrope (T), and a chromophobe (Ch) in a male
animal. Organelles are broken down and sparse.
Mitochondria are severely vacuolated. Nuclei of
the follicle-stimulating hormone gonadotrope and
somatotropes show various extents of pyknosis. In
all degenerative and nondegenerative secretory
cells shown on this micrograph, endoplasmic retic-
ula are dilated, and secretory granules in some of
the cells tend to distribute along the cell membrane
(arrow). Magniﬁcation × 5,400.
Figure 4. Electron micrograph of the pituitary 3
days after DEN injection to a male rat. Cellular
structures are almost completely disrupted and
unrecognizable. Magniﬁcation × 8,400.by using sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis. We confirmed
roughly equal loading by staining the gel
with Coomassie blue.
We used Student’s t-test for all statisti-
cal analyses. We also used the Wilcoxon
rank-sum test when the standard deviation
was relatively large, but it produced the same
statistical significance as the t-test. We pre-
sented p values after correction for multiple
comparisons (36).
Results
Pituitary ultrastructure. In the pituitaries
from control rats at all time points after
DEN administration, most of the granular
cells were of the storage type, characterized
by many secretory granules and an inactive
appearance, with poor development of endo-
plasmic reticula (ER) and Golgi complex
(Figure 1), as described in detail by others
(13,37). We observed moderate congestion
and hemorrhage under light and electron
microscopy in some areas at 1 and 3 days
after DEN treatment of male rats (Figure 2).
Cellular degeneration, which seemed to
involve all cell types containing secretory
granules, was evident on days 1 and 3, but
was less severe on day 7 and disappeared on
day 35. The degenerative alterations were
characterized by sparse and degraded
organelles, increased number of secondary
lysosomes or lysosomal residuals, frequently
appearing crinophagy, lytic or pyknotic
nuclei, and disrupted cell membranes and
cellular structures (Figures 2–5). The secre-
tory granules in degenerating cells were often
located along the cell membrane and some-
times projected out, indicating partial exocy-
tosis before degeneration (Figure 3). In
severely affected areas we observed small
clusters of lytic cells (Figure 4).
Many degenerating and nondegenerated
gonadotropes, somatotropes, and lactotropes
showed dilated ER (Figures 3 and 5) and
hypertrophic Golgi areas, occasionally with
some lightly dense granules inside. These
changes were most evident on days 1 and 3
but were less severe on day 7. The rare cell
types, including corticotropes and thy-
rotropes (Figure 3), showed similar changes
at the corresponding time points. The pitu-
itary ultrastructures looked normal on day
35. The pituitaries from DEN-treated
female rats on day 7 showed changes similar
to those in the pituitaries in the males at the
same time point, and on day 35 the pitu-
itaries looked normal.
Serum levels of GH, prolactin, corticos-
terone, and total testosterone. In DEN-
treated male rats, the serum level of total
testosterone decreased below the detection
limit, whereas the corticosterone level
increased 1 day after DEN treatment (Figure
6). The GH level decreased, but the prolactin
level increased on day 3. We observed no
changes in levels of these hormones at later
time points (data not shown). The GH level
in DEN-treated female rats (26.8 ± 6.5
ng/mL, mean ± SEM) was signiﬁcantly lower
than the control level (78.6 ± 15.2 ng/mL)
on day 7, but not on day 35 (data not
shown). We found no signiﬁcant differences
between treated and control females in the
serum levels of prolactin and corticosterone
(data not shown).
Hepatic CYP expression and androstene-
dione metabolism. In male liver, mRNA
expression of male-specific CYP2C11
decreased to about 1–5% of the respective
control levels during the first week after
DEN treatment and was still less than half of
the control level on day 35 (Figure 7).
According to the literature (6,7,38) and our
experience, liver from DEN-treated rats
should have recovered to almost morphologi-
cally normal 1 week after the treatment.
Therefore, we prepared microsomal proteins
at this time point to study whether the
decrease in CYP2C11 mRNA was associated
with a reduction at the protein level. Western
blot analysis revealed a corresponding
decrease in CYP2C11 protein level on day 7
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Figure 5. Electron micrograph of the pituitary 3
days after DEN injection. Follicle-stimulating hor-
mone gonadotropes show pronouncedly dilated
endoplasmic reticula (ER). Golgi complexes (G) are
hypertrophic, with newly synthesized secretory
granules with light density inside. Two unidentiﬁed
cells (U) are severely degenerated, one of them
with a lysed nucleus. Magniﬁcation × 4,500.
Figure 6. Serum levels of growth hormone, prolactin, total testosterone, and corticosterone at various time points after DEN treatment. Data represent mean ±
SEM of four to ﬁve animals per group. 
aValues of all four animals were lower than the detection limit (0.7 ng/mL). *Signiﬁcantly different from the respective control (p < 0.05).
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*(Figure 8). The mRNA expression of the
female-specific CYP2C12 in control males
was below the detection limit (0.5 amol/µg
TNA) and was also undetectable in DEN-
treated males on days 1 and 35. However,
CYP2C12 expression levels increased slightly
to 4.8 ± 2.8 amol/µg TNA and 10.4 ± 2.4
amol/mg TNA (mean ± SEM) on days 3
and 7, respectively, which were still much
lower than the level in control females (86.1
± 5.0 amol/µg TNA). The appearance of a
faint CYP2C12 protein band in a Western
blot with microsomes from DEN-treated
males on day 7, compared with the undis-
cernible amounts in microsomes from con-
trol males, indicated a slight increase also at
the protein level (data not shown).
Expression of β -actin mRNA in DEN-
treated males increased slightly but signifi-
cantly on day 7, but showed no differences
from the controls at other time points (data
not shown).
The in vitro metabolism of androstene-
dione with microsomes prepared from male
liver on day 7 is presented in Figure 9. The
CYP2C11-catalyzed 16α hydroxylation
decreased to about 10% of the control level,
whereas the other male-predominant reac-
tions, such as 6β and 16β hydroxylation,
showed about 50% decreases. However, the
non–sex-differentiated 7α hydroxylation and
the female-predominant 5α reduction
remained unaffected.
The expression of CYP2C12 mRNA in
DEN-treated versus control female rats was
0.49 ± 0.04 versus 86.1 ± 5.0 amol/µg TNA
on day 7, and 57.0 ± 8.7 versus 87.0 ± 5.7
amol/µg TNA on day 35, respectively; the
differences at both time points were signiﬁ-
cant (p < 0.05). The expression of CYP2C11
in both DEN-treated and control females
was at or below the detection limit. We
observed no differences in β -actin expression
in the female animals either at day 7 or day
35 (data not shown). 
Discussion
The pituitary is refractory to the toxicity of
most substances other than hormone ana-
logues or antagonists (13). So far, hexa-
dimethrine bromide has been the only
substance shown to cause acute pituitary
damage by inducing the rupture of pituitary
blood capillaries (39). In addition, degenerat-
ing and dying somatotropes, in parallel with
a slight decrease in serum GH level, have
been observed in rats with malignant
hepatomas induced by long-term administra-
tion of DEN at a low dose (12). However, it
is unclear from this earlier report whether the
pituitary damage is restricted to soma-
totrophs and results from the tumor burden
or from the chronic toxicity of DEN. The
present study clearly shows that DEN treat-
ment at a necrogenic dose can cause acute
toxicity to various cell types in the adenohy-
pophysis and alter serum levels of several hor-
mones. However, further investigation is still
needed to clarify whether the toxicity is a
direct effect of DEN on the pituitary or an
indirect result of DEN-induced liver damage.
In addition, we observed for its ﬁrst time that
the rat pituitary can recover from severe cell
death to morphologically normal within 5
weeks. The implications of this finding are
currently unclear, and further study is
required to determine whether this finding
means that the rat pituitary can regenerate. 
In addition to cellular damage and cell
death, we observed dilated ER, hypertrophic
Golgi complex, and peripheral localization
of secretory granules in the nondegenerated
gonadotropes, lactotropes, and somatotrophs
in male DEN-treated rats, in association
with transient increase in serum prolactin
level. Similar alterations have been reported
in the pituitary from male rats one to several
days after partial hepatectomy (40,41) and
from the male rats receiving chronic feeding
of liver carcinogen 2-AAF (12) or 3´-methyl-
4-dimethylaminoazobenzene (42). In these
other reports, these alterations were consid-
ered signs of increased cellular activities and
exocytosis in the pituitary cells. Therefore, it
is possible that the similar changes observed
in the present study may reflect increased
cellular activities of nondegenerated pituitary
cells and may be caused by the loss of liver
tissue or the need for liver regeneration, both
of which occur after partial hepatectomy or
treatment with DEN, 2-AAF, or 3´-methyl-
4-dimethylaminoazobenzene. In addition,
the transient but dramatic decrease in the
circulating level of testosterone may stimu-
late cellular activities of gonadotropes.
DEN treatment speciﬁcally decreases the
expression and activities of several male-pre-
dominant enzymes in the male liver and
decreases the CYP2C12 expression in the
female liver. Thus, it is likely that acute DEN
treatment can reduce the sexual differentia-
tion of certain liver functions. These alter-
ations are not likely attributable to liver
necrosis because the non–sex-differentiated
7α -hydroxylation and the female-speciﬁc 5α
reduction of androstenedione were unaffected
in the male liver. Because these results some-
what resemble the effects of hypophysectomy
(43), the observed attenuation of sex differen-
tiation is more likely related to the pituitary
damage, although it is difficult to interpret
why the GH level is decreased only slightly on
day 3 without analysis of its secretory pattern.
In addition, it cannot be excluded at this
point that DEN may affect the hypothalamus
and/or gonads, which in turn inﬂuences the
sex differentiation of certain liver metabolism.
Although the morphologic changes seen
in liver from DEN-treated rats should have
recovered within 1 or 2 weeks (6,7,38),
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Figure 7. Expression of the male-speciﬁc CYP2C11
mRNA in male rat liver at various time points after
DEN treatment. Data represent mean ± SEM
(amol/µg total nucleic acids) of four to five ani-
mals per group.
*Signiﬁcantly different from the corresponding control (p
< 0.05). 
Figure 8. Western blot analysis of CYP2C11 protein
expression in microsomes prepared from male liv-
ers 7 days after DEN treatment. Lanes 1 and 2,
samples from two individual DEN-treated animals
(DEN); lanes 3 and 4, samples from two individual
untreated control animals. Twenty micrograms of
microsomal proteins was loaded in each lane;
roughly equal loading was confirmed by staining
the gel with Coomassie blue (not shown).
Figure 9. Microsomal 7α -, 6β -, 16β - and 16α -
hydroxylation and 5α -reduction of 4-[4-
C14]androstene-3,17-dione in male rats 7 days
after DEN injection. Data represent mean ± SEM
of four four animals per group. 
*Signiﬁcantly different from the control (p < 0.05).
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*expression of CYP2C11 in males and
CYP2C12 in females was still subnormal
after 5 weeks. Similarly, Carr et al. (44)
reported that DEN-induced decreases in
hepatic receptors for epidermal growth fac-
tor and insulin returned to only 60% of the
normal levels 1 month after DEN treatment,
and pronounced decreases in these receptors
can be induced by a non-necrogenic dose of
DEN (25 mg/kg). Thus, the decreases in
these receptors might be irrelevant to the
loss of hepatocytes. Given these facts, DEN-
induced disturbance of certain liver func-
tions seems to last much longer than the
time needed for morphologic recovery of
the liver. Therefore, in multistage models of
hepatocarcinogenesis that are initiated by a
necrogenic dose of DEN, promoting agents
might better be started at least 5 weeks after
DEN treatment, not 2 weeks as originally
designed (5), when sex difference is one
concern of the study.
In conclusion, a single intraperitoneal
injection of DEN at a dose of 200 mg/kg is
used for the initiation in many animal mod-
els of multistaged hepatocarcinogenesis. This
dose of DEN may cause pituitary damage,
disturb serum levels of several hormones, and
induce a long-lasting reduction of certain sex-
differentiated liver functions, indicating a
profound impact on the endocrine system.
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